Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 5,126 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Interventions: Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study, Sorafenib Tosylate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 659
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more

Conditions: Frailty, Lung Tranplant Candidate
Interventions: XFIT; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: San Francisco, California • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Introduction of Teledermatology Mobile Apps
Interventions: Direct to patient facing mobile apps introduction; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: San Francisco, California • Durham, North Carolina • Providence, Rhode Island

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy; Biological · Drug · Procedure
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Posttraumatic Stress Disorder
Interventions: Therapy, midomafetamine HCl, Placebo; Behavioral · Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: North Hollywood, California • San Francisco, California • Boulder, Colorado + 6 more

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Development of Ptosis After Vitreo-retinal Surgery
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions: Vyvanse (lisdexamfetamine dimesylate), NRP104; Drug
Lead sponsor: New River Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Irvine, California + 40 more

Conditions: Neonatal Seizures
Interventions: Surveys, EEG; Other
Lead sponsor: University of Michigan; Other
Eligibility: 0 Weeks to 24 Months
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: San Francisco, California • Stanford, California • Washington D.C., District of Columbia + 5 more

Conditions: Type 1 Diabetes
Interventions: TZIELD (teplizumab-mzwv); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 37
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more

Conditions: Mild to Moderate Asthma
Interventions: CDX-622; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Coagulopathy
Interventions: RapidTEG test; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: San Francisco, California • Portland, Oregon • Houston, Texas

Conditions: Infections, Urinary Tract, Nephrolithiasis
Interventions: Duration of antibiotics; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Urinary Tract Infections
Interventions: Computer-assisted treatment group, Usual care group; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Fresno, California • Oakland, California • San Francisco, California

Conditions: Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions: Cabiralizumab, Nivolumab; Biological
Lead sponsor: Five Prime Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 39
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Multiple Myeloma
Interventions: Isatuximab, Carfilzomib, Dexamethasone; Biological · Drug
Lead sponsor: Thomas Martin, MD; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more

Conditions: Tuberculosis
Interventions: RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 2 Years and older
Enrollment: 8,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Epilepsy
Interventions: Activa™ PC and Percept™ PC Neurostimulation Systems; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Actinic Keratoses, Skin Neoplasms
Interventions: Aminolevulinic Acid, Vehicle; Drug · Other
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Miami, Florida + 4 more

Conditions: Heart Failure
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 4,874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 172
States / cities: Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more

Conditions: Induction of Labor
Interventions: Induction of labor with foley balloon - 60cc of saline, Induction of labor with foley balloon with 30cc; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: Female only
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Exercise-based Frailty Intervention in Lung Transplantation (XFIT)

Teledermatology Mobile App: Patient Facing

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study

Registry for Stage 2 Type 1 Diabetes

A Study of CDX-622 in Participants With Mild to Moderate Asthma

A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients

Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml